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Background: Familial adenomatous polyposis (FAP) is a condition typically caused by 76 
 77 
pathogenic germline mutations in the APC gene. In addition to colon polyps, individuals 78 
 79 
with FAP have a substantially increased risk of developing papillary thyroid carcinoma 80 
 81 
(PTC). Little is known about the events underlying this association, and the prevalence 82 
 83 
of somatic “second-hit” mutations in APC is controversial. 84 
 85 
Methods: Whole genome sequencing was performed on paired thyroid tumor and 86 
 87 
normal DNA from 12 FAP patients who developed PTC. Somatic mutation profiles were 88 
 89 
compared with clinical characteristics and previously sequenced sporadic PTC cases. 90 
 91 
Germline variant profiling was performed to assess the prevalence of variants in genes 92 
 93 
previously shown to have a role in PTC predisposition. 94 
 95 




Seven patients also had somatic mutations in APC, and seven patients harbored 98 
 99 
somatic mutations in KMT2D, which encodes a lysine methyl transferase. Mutation of 100 
 101 
these genes is extremely rare in sporadic PTCs. Notably, only two of the tumors 102 
 103 
harbored the somatic BRAF p.Val600Glu mutation, which is the most common driver 104 
 105 
mutation found in sporadic PTCs.  106 
 107 
Six tumors displayed cribriform-morular variant of PTC (PTC-CMV) histology, and all six of these  108 
 109 
had somatic mutations  in APC. Additionally,  9 FAP-PTC  patients  had rare germline variants in  110 
 111 
genes that were previously associated with thyroid carcinoma. 112 
 113 
Conclusions: Our data indicate that FAP-associated PTCs typically have distinct 114 
 115 
mutations compared to sporadic PTCs. Roughly half of the thyroid cancers that arise in 116 
 117 
FAP patients have somatic “second-hits” in APC, which is associated with PTC-CMV 118 
6 
 
histology. Somatic BRAF p.Val600Glu variants also occur in some FAP patients, a 119 
 120 
novel finding. We speculate that in carriers of heterozygous pathogenic mutations of 121 
 122 
tumor suppressor genes such as APC, a cooperating second-hit somatic variant may 123 
 124 
occur in a different gene such as KTM2D or BRAF, leading to differences in 125 
 126 
phenotypes.  The role of germline variance in genes other than APC (9 of 12 patients in this  127 
 128 
series) needs further research. 129 
 130 
 131 





In addition to colon polyps and colorectal cancer, patients with familial adenomatous 135 
 136 
polyposis (FAP) have an increased risk to develop extracolonic malignancies and 137 
 138 
benign conditions/tumors. Of particular interest is the frequent occurrence of papillary 139 
 140 
thyroid cancer (PTC) which is some 100 times more prevalent in FAP patients than in 141 
 142 
the general population (1). FAP is typically caused by germline mutations in the APC 143 
 144 
gene that result in a truncated APC protein, and inevitably develops into colorectal 145 
 146 
cancer (CRC) when somatic “second hit” mutations in APC occur in colon cells (2). 147 
 148 
Previous studies have confirmed the existence of such “second hits” in the APC gene in 149 
 150 
a subset of thyroid cancers that occur in FAP patients, (3) but this remains 151 
 152 
controversial, as other reports have concluded that the APC gene is rarely somatically 153 
 154 




FAP-associated PTCs often display cribiform-morular variant (CMV) histology, which is 157 
 158 
otherwise extremely rare (~0.2% of all thyroid cancers) (7). Altogether about half of all 159 
 160 
CMV-PTCs occur in FAP patients (7,8). In general PTC is about three times more 161 
 162 
common in females than in males, and this ratio is even higher in PTC-CMV patients 163 
 164 
and FAP-associated PTCs (7). Molecular characteristics of PTC-CMV include mutations 165 
 166 
in the CTNNB1 and/or  PIK3CA genes and RET/PTC rearrangements.  No oncogenic 167 
 168 
BRAF mutations  have  so far been reported  in CMV-PTCs  or FAP-associated PTCs; 169 
 170 
however  a comprehensive assessment of the somatic alterations  that  occur in FAP- 171 
 172 
associated PTCs has not been conducted. To better understand the germline and 173 
 174 
somatic variants found in this unique tumor type and to try to learn more about the genetic  175 
 176 
mechanisms of thyroid cancer development in individuals with FAP-associated 177 
 178 




and normal DNA from 12 FAP-associated PTC patients. 181 
 182 
 183 




All patients with both FAP and PTC were selected from the PTC patient repositories at 188 
 189 
the Cleveland Clinic and the Helsinki University Hospital. Histological review of tumor 190 
 191 
sections was performed to confirm the presence of cancer in the resected thyroid. This 192 
 193 
study was limited to patients with germline APC mutations detected by clinically- 194 
 195 
approved testing methods. All patients provided written informed consent and studies 196 
 197 
were performed in accordance with the declaration of Helsinki, and approved by institutional 198 
 199 






DNA extraction and sequencing 204 
 205 
DNA was extracted from paraffin embedded thyroid tumors and adjacent normal tissue 206 
 207 
(patients 2, 4, 5, 7, 8, 9, 10, and 12) using QIAamp DNA FFPE Tissue Kits (Qiagen, 208 
 209 
Hilden, Germany), or from blood (patients 1, 3, 6, and 11) using a previously described 210 
 211 
non-enzymatic DNA-extraction method (9). DNA samples were quantified using a Qubit 212 
 213 
3.0 Fluorometer (Thermo Fisher Scientific, Waltham, MA) and fragment size was 214 
 215 
assessed using a 2100 Bioanalyzer system (Agilent Technologies, Santa Clara, CA). All 216 
 217 
samples had average fragment sizes > 1500bp. Library preparation and paired-end 218 
 219 
genome sequencing was performed by Novogene (Beijing, China), using Truseq Nano DNA HT 220 
 221 
Sample Preparation Kits (Illumina, San Diego, CA) and HiSeq 4000 instruments (Illumina, San 222 
 223 









The quality of sequences was confirmed using FASTQC software. All samples had 231 
 232 
>99% of reads mapped, and all samples had >90% of bases with phred-scaled quality 233 
 234 
scores > 30. Mapping  was done with Burrows-Wheeler Aligner to the Genome 235 
 236 
Reference Consortium Human Build 37. Samples were sorted  with SamTools, 237 
 238 
duplicates  were marked  with Picard, and variants were called with GATK then 239 
 240 
annotated with ANNOVAR. For somatic and germline variant analysis, paired .vcf files 241 
 242 
from each tumor and matching adjacent normal thyroid or blood sample were loaded 243 
 244 
into BasePlayer software (10). Variants present in the tumor sample and absent but 245 
 246 
covered in the paired germline DNA were considered somatic. Publicly available data 247 
 248 
from the American Association for Cancer Research Genomics Evidence Neoplasia 249 
 250 
Information Exchange (AACR-GENIE) and The Cancer Genome Research Atlas 251 
 252 




Somatic variant signature analysis was performed using the R package 255 
 256 
DeconstructSigs,(11) and the 30 signatures described in the Catalog of Somatic 257 
 258 
Mutations in Cancer (COSMIC) Mutational Signatures (v2-March 2015). 259 
 260 
Somatic loss of heterozygosity (LOH) was determined using BasePlayer software (10) 261 
 262 
by comparing the allelic ratios of sequenced germline variants to their corresponding 263 
 264 
ratios in the matched tumor sample as described (12,13). A tumor to normal ratio of 265 
 266 
≤0.6 or ≥1.67 was considered LOH, and a tumor to normal ratio of 0.6-0.8 or 1.25-1.67 267 
 268 












The 12 FAP-PTC patients in our cohort consisted of 4 males and 8 females (Table 1). 279 
 280 
Five patients displayed classic PTC histology (three males and two females), six 281 
 282 
patients had PTC-CMV (one male and five females), and one female had follicular 283 
 284 
variant of papillary thyroid carcinoma. Number of the tumors varies from 1 to 2 per individual  285 
 286 
and tumor sizes varies between 0.1 cm and ? All patients in our sample set were diagnosed 287 
 288 
with FAP before thyroid cancer, with an average age at FAP diagnosis of 25 years 289 
 290 
(range 12-44 years), and an average age at PTC diagnosis of 38 years (range 20-62 291 
 292 
years). Patients were diagnosed with thyroid carcinoma on average 15 years after 293 
 294 
being diagnosed with FAP (range 1-46 years after FAP diagnosis). This cohort 295 
 296 
displayed characteristics typically associated with FAP, including colorectal cancer, 297 
 298 





Whole genome sequencing was performed on paired tumor and normal DNA from all 302 
 303 
12 cases. An oncoprint of the most commonly mutated genes is presented in Figure 1a. 304 
 305 
Seven patients had somatic “second-hit” mutations in APC, including one patient with 306 
 307 
clear somatic LOH of APC and two patients with putative LOH. The lysine methyl 308 
 309 
transferase gene KMT2D was also mutated in seven of the 12 PTC tumors, and 310 
 311 
another  KMT2  family member, KMT2C was mutated in three patients (four mutations).  The  312 
 313 
recurrently mutated genes  in these samples were strikingly  different  from genes that are  314 
 315 
typically mutated in sporadic PTC, as evidenced by comparison with the AACR-GENIE and 316 
 317 
TCGA of PTC data sets (Supplementary Table 1). Specifically, mutations in KMT2C, 318 
 319 
KMT2D and APC were only detected in <3% of sporadic cases. Conversely, BRAF is 320 
 321 
mutated in about 60% of all PTCs, and the vast majority of these mutations consist of the 322 
 323 




cases harbored BRAF mutations (both p.Val600Glu). Notably, neither of these samples 326 
 327 
had somatic APC mutations. RET/PTC translocations are also common in typical 328 
 329 
PTCs,(14) however, in our cohort, there was no evidence of breakpoints between exons 330 
 331 
11 and 12 in RET. Therefore, it is likely that none of the APC-associated PTCs we 332 
 333 
sequenced harbored RET/PTC or other RET translocations/inversions.  We did not detect  334 
 335 
any somatic mutations in the Ras genes (NRAS, HRAS and KRAS), which are recurrently  336 
 337 
mutated in sporadic PTC. 338 
 339 
All clinically detected germline nonsense, frameshift and insertion/deletion variants in 340 
 341 
the APC gene were validated in our genome sequencing. Three samples had complex 342 
 343 
APC germline mutations: patient 11 had a heterozygous ~23Mb deletion of  344 
 345 
chromosome 5q that contained APC, patient 4 had a deletion of exons 15-16 346 
 347 
(NM_000038, coding exons 14-15), and patient 1 had a C to T transition within intron 11 348 
 349 




have previously described (Table 2) (15). The remaining nine patients all had frameshift 352 
 353 
and nonsense germline mutations in the APC coding sequence, located between 354 
 355 
codons 471 and 1465 (Fig. 1b, Table 2). The “second-hit” somatic variants in APC were 356 
 357 
more spread out, and there was not an obvious correlation between the location of the 358 
 359 
germline mutation in APC and the somatic second hit, in contrast to reports that the 360 
 361 
location of the germline FAP-associated APC mutation can influence the position of the 362 
 363 
somatic APC variant in colorectal cancer secondary to FAP (Fig. 1b, Table 2) (16). 364 
 365 
 366 
We examined the specific base pair substitutions in the mutations in these samples and 367 
 368 
compared them to described mutational  signatures  associated with different cancers 369 
 370 
and cancer subtypes  (17). Most samples showed strong correlations  with expression 371 
 372 




strand break-repair by homologous recombination), 5 (pan-cancer with unknown 375 
 376 
etiology), 12 (unknown etiology signature found in liver cancer) and 20 (defective DNA 377 
 378 
mismatch repair) (Fig. 2a, b). Patient 6’s tumor exhibited a strong signal for mutation 379 
 380 
signature 6, which is seen in microsatellite unstable tumors that have DNA mismatch 381 
 382 
repair defects, and mutation signature 19, which is an unknown etiology signature found 383 
 384 
in pilocytic astrocytomas (Fig. 2c) (17,18,19,20). Notably, patient 6 did not have 385 
 386 
somatic mutations in MLH1, PMS2, MSH2, or MSH6, and also did not have likely 387 
 388 
pathogenic germline variants in these genes. 389 
 390 
 391 
Finally we examined the germline variants in these samples for alleles that might play a 392 
 393 
role  in  thyroid   cancer,  specifically   focusing  on  nonsynonymous variants in genes 394 
 395 
previously implicated in familial thyroid cancer (21). Because rare 396 
 397 




on family studies (22), we only examined nonsynonymous variants 400 
 401 
with a population minor allele frequency less than 0.01 in the gnomAD database. We 402 
 403 
found 9 of the FAP-PTC patients had germline variants in 17 different genes, which were 404 
 405 
previously found to harbor variants associated with familial thyroid carcinoma (21)  406 
 407 
(Supplementary Table 2). Interestingly, there were several variants in the RNF213 408 
 409 
gene in three different  FAP-PTC patients.  RNF213 has been found  to be mutated in liver 410 
 411 
cancer (23) and all three of the patients (4, 5, 8) with RNF213 variants had a strong signal for  412 
 413 
mutational signature 12 (Fig. 2a), which is linked to liver cancer. The p.Arg752Leu FGD6 variant  414 
 415 
was found in two patients, one from the USA (patient 9) and one from Finland (patient 1). 416 
 417 
FGD6 is located on chromosome 12q22, and this band has been observed to be amplified 418 
 419 







It is surprising, although not entirely unexpected, that we detected somatic second hits 425 
 426 
in APC in over half of the FAP-PTC tumors we analyzed. Cetta et al. reported that 427 
 428 
somatic mutations in APC do not occur in FAP-associated PTC, (4,25) but in contrast, 429 
 430 
somatic second hit mutations in APC were previously reported by other groups (3,5,6). 431 
 432 
One explanation of this apparent contradiction is the recently improved sequencing  433 
 434 
methodology, and the failure of some researchers  to examine the entire 435 
 436 
APC coding sequence. 437 
 438 
 439 
Mechanistically, pathogenic nonsense and frameshift APC mutations lead to truncated 440 
 441 
APC protein products that are unable to interact with the cytoplasmic complex that 442 
 443 
mediates β-catenin degradation. Thus, the β-catenin/Lef/Tcf complex remains 444 
 445 




enhanced cellular migration, proliferation and loss of differentiation (26). Our finding is 448 
 449 
consistent with the idea that somatic second hits and/or LOH in APC further add 450 
 451 
cancerous properties to the cell and likely contribute to malignant transformation. 452 
 453 
 454 
Our identification of the somatic BRAF p.Val600Glu mutation in two patients is a novel 455 
 456 
finding, as to our knowledge, no single case has been described in the literature where 457 
 458 
oncogenic BRAF mutations occur in either FAP-PTC or PTC-CMV 459 
 460 
(7,27,28,29,30,31,32). This implies that some PTCs arising in the context of germline 461 
 462 
pathogenic APC variants can share the same driver mutations as sporadic PTCs. The 463 
 464 
mutual exclusivity of the somatic APC and BRAF mutations is consistent with different 465 
 466 
molecular subtypes of PTC occurring in different FAP patients. The tumors with BRAF 467 
 468 
p.Val600Glu mutations displayed typical PTC histology, and occurred in one male and 469 
 470 




entirely female (6 to 1, female to male), and in six of seven cases showed PTC-CMV 473 
 474 
histology. Interestingly, the patient with a somatic APC mutation who did not have PTC-CMV  475 
 476 
histology (patient 7) harbored the most 3’ APC mutation we detected. The mutated APC  477 
 478 
protein in patient 7 likely retains some beta-catenin binding ability, and we speculate this  479 
 480 




What does it mean that 58% and 33% of the PTC tumors in these FAP patients have 485 
 486 
somatic variants in the KMT2D and KMT2C genes, respectively? KMT2D and KMT2C 487 
 488 
are methyl transferase genes that encode important pieces of the COMPASS complex 489 
 490 
(33). Pathogenic somatic mutations in both of these genes have been detected in many 491 
 492 
different cancers, such as oropharyngeal squamous cell carcinoma, T-cell lymphoma, 493 
 494 
bladder cancer, head and neck cancer, and breast and endometrial cancers, but are 495 
 496 




been shown to contribute to increased mutational burden and genome instability  (38).  499 
 500 
Prompted by KMT2D somatic variants, we looked for biological link between APC and KMT2D  501 
 502 
genes, and to our surprise, it seems that also KMT2D might be involved in WNT signaling.  503 
 504 
KMT2D together with ALK gene are connected with CTNNB1 (β-catenin) (Pinckney et al. 2018,  505 
 506 
Applied Cancer Research, 38:13), so it is not surprise that in some tumors instead of APC,  507 
 508 
somatic mutations occurs in KMT2D. 509 
 510 
We speculate that the detected somatic variants in these genes  511 
 512 
(particularly KMT2D) might be important in the context of deactivated WNT signaling caused by  513 
 514 
FAP-associated germline APC mutations, and evidence of epigenetic dysregulation in these  515 
 516 
cases warrants further investigation. Our data implicate that the mutations in KMT2D  may be  517 
 518 





The overall female to male ratio in our cohort is less skewed towards  522 
 523 
females than other reports of FAP-PTC patient demographics (7,39). For example, Lam et  524 
 525 
al.(7) reported that the female to male ratio in PTC-CMV is 31 to 1, whereas in our cohort 526 
 527 
there was only a 5 to 1 ratio of females to males among patients with PTC-CMV. 528 
 529 
However, we do acknowledge that the modest size of our cohort does not lend itself to 530 
 531 
definitive conclusions regarding sex ratios. Seven of the twelve patients had desmoid 532 
 533 
tumors, which is not surprising given that this a common feature of FAP patients 534 
 535 
(29,40,41,42,43,44).  536 
 537 
 538 
Our study is the first that suggests mutations in genes other than APC can cooperate with the  539 
 540 
germline APC variant  in FAP patients  to drive  thyroid  cancer. Also, our  541 
 542 




process. Our data are consistent with a model where the pathogenic  germline APC 545 
 546 
variants  act as “gatekeepers”  in the thyroid.  Some patients, almost always females, 547 
 548 
acquire somatic second hits in APC that drive a thyroid cancer with CMV histology. In 549 
 550 
other cases, oncogenic activating mutations somatically occur in BRAF, similar to 551 
 552 
sporadic thyroid cancers. In patients who lack clear driver mutations in APC or BRAF, 553 
 554 
an intriguing possibility is that somatic variants in other genes (e.g. KTM2D, KMT2C and 555 
 556 
others) may act as cancer drivers in the thyroid. This concept postulates that a somatic 557 
 558 
heterozygous variant in a gene such as KTM2D can act as a trigger of the malignant 559 
 560 
transformation of a cell heterozygous for pathogenic variant in another gene (i.e. APC), and 561 
 562 
is in line with the concept that multiple events contributing different cancerous properties 563 
 564 
to a cell need to occur in order for a malignancy  to develop  and proliferate  (45). To 565 
 566 









It is striking that 9 out of the 12 patients we sequenced harbored rare nonsynonymous 574 
 575 
mutations in 17 selected genes known to be associated with familial thyroid cancer. This 576 
 577 
is consistent with the idea that additional germline variants other than of APC can contribute 578 
 579 
to PTC formation in FAP  patients.  Further studies are necessary to unequivocally prove 580 
 581 
a causative role for the implicated  germline variants  in FAP-associated  PTC, and explore 582 
 583 
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Table 1. Clinical characteristics of the 12 PTC patients with FAP  














1 Male PTC-CMV 12 30 1 9 cm Incidental desmoid tumors 
2 Female PTC-CMV 21 35 





3 Female PTC-CMV 43 45 
1 2.4 cm Mass in the neck, 
“self finding” 
. 
4 Female PTC-CMV 33 35 





5 Female PTC-CMV 18 43 





6 Female PTC-CMV 21 21 





7 Female PTC 18 42 




8 Male PTC 20 44 







9 Female PTC 16 62 
1 0.4 cm Screening 
ultrasound 
ampullary cancer 
10 Male PTC 23 28 
1 1.6 cm Screening 
ultrasound 
desmoid tumors 
11 Female PTC-FV 24 24 
1 0.9 cm Jugular vein 
thrombus 
desmoid tumors 
12 Male PTC 44 45 













Additional file 4: Figure S1. ALK and KMT2D (MLL2) converge on CTNNB1. An 1 
evaluation of the potential role of the gene products from mutated genes in our 2 
cohort that are associated with negative outcomes was completed to potentially 3 
identify pathways that could be targeted for novel therapy in this young group. 4 
String®, a protein-protein network modeling website sponsored by the String 5 
Consortium and the Swiss Institute of Bioinformatics (SIB) [], was used to 6 
postulate how the gene mutations were connected in biochemical pathways that 7 
could potentially create the carcinogenic phenotype. In our cohort, ALK and 8 
KMT2D (MLL2) gene mutations were found to be associated with both ovarian 9 
and endometrial negative outcomes in patients with neuroendocrine histology. In 10 
the String program, the ALK and KMT2D proteins, while being involved in 11 
multiple pathways, appear to converge on CTNNB1, a key member of the Wnt 12 
pathway. The Wnt pathway is important in cell adhesion and maintenance of an 13 
appropriate cell cycle and has been found to be compromised in a variety of 14 
cancers. Additionally, dysregulation of the Wnt pathway has recently been 15 
implicated in maintenance of cancer stem cells, metastasis and immune control 16 
(Zhan T et al., Oncogene 2017; 36:1461–1473). The String algorithm also revealed 17 
that HSP90AA1 is also involved in this complex pathway. HSP90AA1 has been 18 
shown to be a prognostic indicator of both liver and breast cancers. () (DOCX 687 19 
kb) 20 
 21 
